Clinical Trial Update: A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the safety and pharmacokinetics of QTORIN Rapamycin 3.9% anhydrous gel for pachyonychia congenita is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pachyonychia Congenita

Drugs mentioned

• QTORIN Rapamycin 3.9% anhydrous gel (Rapamycin)

Snippet

Sponsor: Palvella Therapeutics, Inc. | Conditions: Pachyonychia Congenita | Phase 3 | Status: RECRUITING